CroíValve, a Dublin, Ireland-based medical device company developing a novel treatment for tricuspid regurgitation, raised €8m in Series A funding.
The round was led by the HBAN (Halo Business Angel Network) MedTech and Irrus Syndicates, alongside existing investors Atlantic Bridge University Fund, Broadview Ventures, SOSV and Enterprise Ireland and new investors Elkstone, Ascentifi and DBIC.
The company intends to use the funds for European Feasibility Study of the CroíValve Transcatheter Tricuspid DUO Coaptation Valve System.
Led by Dr. Lucy O’Keeffe, CEO, CroíValve is advancing a novel treatment for tricuspid regurgitation, a severe heart condition that occurs when the tricuspid valve fails to close properly. The DUO System consists of a coaptation valve implant that works in tandem with the native tricuspid valve to restore valve function. The device is delivered percutaneously and is secured using a novel anchor system which leaves the delicate right heart chamber and native valve apparatus untouched. It is designed to be implanted in a straightforward procedure using standard imaging and is suitable for a broad patient cohort, including those who are challenging to treat with other valve repair and replacement technologies.
Additionally, CroíValve added Dr. Azin Parhizgar, Ph.D., a medical device entrepreneur in structural heart, to its Board of Directors. In addition, Helen Scotch has joined the Senior Leadership Team as Vice President of Clinical and Regulatory Affairs.
FinSMEs
07/02/2022